RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
Slow, steady progress on hair loss treatments such as finasteride, minoxidil, microneedling and Nizoral; the need for patience when using these treatments over a period of months or years; and how to deal with discouragement due to slow progress.
The user shared progress pictures over four months using topical finasteride, topical and oral minoxidil, topical RU58841 daily, and oral dutasteride once a week. The pictures are spaced about a month apart.
A user's progress with using Minoxidil 5% twice daily, dermarolling 1.5mm once per week and ketoconazole 2% shampoo for 2.5 months. Other users have suggested that the user should also use finasteride in order to maintain their results.
A user initially had side effects from finasteride, attributed them to anxiety and the nocebo effect, and after resuming the drug, experienced positive effects and now warns against misinformation about Post Finasteride Syndrome.
Hims reactivated a subscription without consent, leading to unauthorized charges for Finasteride and Minoxidil products, and refused to issue a refund until a bank dispute was filed. Users discussed alternative, cheaper sources for these treatments and shared similar negative experiences with Hims.
A user's experience using dutasteride, minoxidil, ketoconazole, vitamin D, scalp massage, exercise, and avoiding vaping and 2-in-1 shampoo/conditioner to treat hair loss; they also discussed the side effects of finasteride.
The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
Hair loss due to DHT is causing distress, with Minoxidil, finasteride, and RU58841 being potential treatments. The conversation includes humor and frustration about the topic.
Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
A 25-year-old noticed thinning hair at the temples and started using finasteride (1mg/day) for two months, along with keto shampoo twice a week and vitamins like vitamin D, biotin, and zinc. They are seeing some results and are hopeful about regaining lost hair.
A user shared their positive experience with the telehealth service DocBright, highlighting its affordability and effectiveness in prescribing finasteride, oral minoxidil, and ketoconazole. They noted the service's unique ability to provide a prescription at age 17 but criticized the unprofessional communication with the dermatologist.
A user had a bad experience with MV Supplements when their Pyril powder and ethanol order leaked during shipping, making the products unusable. Despite contacting support and providing evidence, the company's return policy did not allow for a refund or replacement.
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
Hair growth progress using Propecia, Minoxidil, dermarolling, ketoconazole shampoo, and vitamins. Noticeable hair growth in temples after 3 months and 10 days.
A satirical discussion about a hair transplant, with humorous comments on graft placement and clinic choice. The conversation includes references to a "Rebuild a Scalp Clinic" and jokes about using pubic hair and overharvesting.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
A 30-year-old male experienced rapid hair shedding over 6-7 months due to stress, depression, and nicotine/alcohol use, but has since stopped these habits. He seeks advice on remedies, medications, or diet changes to address hair loss.
The user experienced significant hair shedding despite long-term use of finasteride and minoxidil, considering switching to dutasteride and increasing minoxidil dosage. Suggestions included trying topical minoxidil and adding a topical antiandrogen, but avoiding RU58841.
The user is using oral minoxidil (5mg) and dutasteride (0.5mg) daily for hair regrowth. They noticed increased thickness in the crown area after starting these treatments.
User experienced hair density decrease after 1 year of finasteride. Others shared similar experiences, suggesting it could be a temporary shed and discussed various treatments like dutasteride, minoxidil, dermaroller, and ketoconazole.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.